Last reviewed · How we verify
γδT Cell infusion agent
At a glance
| Generic name | γδT Cell infusion agent |
|---|---|
| Sponsor | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases (PHASE1)
- Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (PHASE1)
- Clinical Study of Universal CD19 CAR-γδT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma (PHASE1)
- QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (PHASE1)
- Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors (PHASE1)
- Adoptive TKC Transfer Combined With Chemotherapy for Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE1)
- γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse (EARLY_PHASE1)
- γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- γδT Cell infusion agent CI brief — competitive landscape report
- γδT Cell infusion agent updates RSS · CI watch RSS
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. portfolio CI